OPEN LABEL PHASE TWO TRIAL OF RADIUM RA 223 DICHLORIDE WITH CONCURRENT ADMINISTRATION OF ABIRATERONE ACETATE PLUS PREDNISONE IN SYMPTOMATIC CASTRATION-RESISTANT (HORMONE-REFRACTORY) PROSTATE CANCER SUBJECTS WITH BONE METASTASIS: